1. Use of Reversal Options for Neuromuscular Blockade: Improving Patient Safety

2. This program will include a discussion of off-label treatment not approved by the FDA for use in the United States.

3. Program Goals

4. Achieving Optimal Surgical Conditions

5. Use of NMB

6. Deep NMB vs No NMB

7. Risk of Residual Paralysis After NMB

8. High Risk of Residual NMB

9. Complications of NMB

10. Postoperative Pulmonary Complications

11. Risk Factors for Pulmonary Complications

12. Preventing Complications of Residual NMB

13. Pros and Cons of Neostigmine

14. Neostigmine: Time of Effect

15. Sugammadex Pros and Cons

16. Sugammadex Dosing Recommendations

17. Sugammadex vs Neostigmine: Moderate NMB

18. Sugammadex vs Neostigmine: Moderate NMB (cont)

19. Sugammadex vs Neostigmine: Deep NMB

20. Sugammadex vs Neostigmine: Deep NMB (cont)

21. Good Candidates for Sugammadex

22. Sugammadex vs Neostigmine in the Morbidly Obese

23. Residual NMB in Elderly Patients

24. Residual NMB in Elderly Patients (cont)

25. How Deep NMB Improves Surgical Conditions

26. Selection of an Appropriate Reversal Agent

27. Other Considerations With Sugammadex Use

28. Case 1: When Sugammadex May Be Helpful

29. Case 2: When Sugammadex May Be Helpful

30. Case 2: When Sugammadex May Be Helpful (cont)

31. Case 3: When Sugammadex May Be Helpful

32. Case 3: When Sugammadex May Be Helpful (cont)

33. Case 4: When Sugammadex May Be Helpful

34. Case 5: When Sugammadex May Be Helpful

35. Surgery and Anesthesiology Collaboration

36. Conclusions

37. Conclusions (cont)

38. Abbreviations

39. Abbreviations (cont)